Recent advances in biomakers for cancer diagnosis and treatment

被引:68
|
作者
Manne, U [1 ]
Srivastava, RG
Srivastava, S
机构
[1] Univ Alabama, Dept Pathol, Tuscaloosa, AL 35487 USA
[2] Natl Canc Inst, Organ Syst Branch, Bethesda, MD 20892 USA
[3] Natl Canc Inst, Canc Biomarkers Res Grp, Bethesda, MD 20892 USA
关键词
D O I
10.1016/S1359-6446(05)03487-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
With the availability of new technologies and the increased interest of medical practitioners to use molecular biomarkers in early detection and diagnosis, and in the prediction of therapeutic treatment efficacy and clinical outcomes, the academic and research institutions, as well as the pharmaceutical industry have increased their efforts to develop novel molecular biomarkers for several human diseases, including cancer. The identification of molecular biomarkers also enables the development of a new generation of diagnostic products and to integrate diagnostics and therapeutics. This integrated approach will aid in 'individualizing' the medical practice. Here, we address issues related to the development of biomarkers, novel technological platforms used for drug development, future technologies and strategies for validating biomarkers for their clinical utility.
引用
收藏
页码:965 / 976
页数:12
相关论文
共 50 条